Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. |
C3G | Phase3 | Brazil China United States |
NCT04817618 |
A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis |
Multiple Sclerosis | Germany | NCT06551519 | |
A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura® |
Asthma | South Korea | NCT05217810 | |
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. |
Oligometastatic Prostate Cancer (OMPC) | Phase3 | Argentina Australia Austria Belgium Brazil Canada China Czechia France Germany Greece Hungary Israel Italy Japan Malaysia Mexico Netherlands Puerto Rico Singapore Slovakia Spain Switzerland Taiwan United Kingdom United States View all |
NCT05939414 |
Dabrafenib and/or Trametinib Rollover Study |
Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma | Phase4 | Spain United States |
NCT03340506 |
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease |
Sickle Cell Disease | Phase1, Phase2 | United States | NCT06546670 |
A Post Marketing Surveillance on Piqray in Korea |
Breast Cancer | South Korea | NCT05293470 | |
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN |
IC-MPGN | Phase3 | Argentina Brazil Canada Czechia Denmark France Germany Greece India Israel Italy Japan Netherlands Poland Slovakia South Korea Spain Switzerland Taiwan Turkey (Türkiye) United Kingdom United States Vietnam View all |
NCT05755386 |
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS) |
Atypical Hemolytic Uremic Syndrome | Phase3 | France Germany Italy Japan Spain Turkey (Türkiye) United Kingdom View all |
NCT05935215 |
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. |
Lymphatic Malformations | Phase2, Phase3 | Argentina Australia Belgium France Germany Italy Netherlands Spain Switzerland United States View all |
NCT05948943 |